Inscripta

OverviewSuggest Edit

Inscripta is a gene editing technology company dedicated to developing a family of CRISPR enzymes, MADzymes, bespoke nucleases for researchers and commercial partners. The Company also creates a full suite of gene editing tools, including software, instruments, and reagents that increase the speed and efficiency of precision gene editing.
TypePrivate
Founded2015
HQBoulder, US
Websiteinscripta.com

Latest Updates

Employees (est.) (May 2019)82(+4%)

Key People/Management at Inscripta

Kevin Ness

Kevin Ness

CEO
Ryan Gill

Ryan Gill

CSO & Co-Founder
Don Masquelier

Don Masquelier

VP Engineering
Dianna Devore

Dianna Devore

General Counsel
Todd Rubano

Todd Rubano

VP Software
Michael Graige

Michael Graige

VP Product Development
Show more

Inscripta Office Locations

Inscripta has offices in Boulder and Pleasanton
Boulder, US (HQ)
5500 Central Ave #220
Pleasanton, US
7026 Koll Center Pkwy #225
Show all (2)

Inscripta Financials and Metrics

Summary Metrics

Founding Date

2015

Inscripta total Funding

$104 m

Inscripta latest funding size

$20 m

Time since last funding

2 months ago

Inscripta investors

Inscripta's latest funding round in April 2019 was reported to be $20 m. In total, Inscripta has raised $104 m
View all funding rounds

Inscripta Online and Social Media Presence

Embed Graph

Inscripta News and Updates

Inscripta Hires Chief Commercial Officer Jason T. Gammack to Bring Gene-Editing Tools to Market

BOULDER, Colo., Nov. 1, 2018 /PRNewswire/ -- Inscripta™, a leading gene-editing technology company, today announced the addition of Jason T. Gammack as the company's first chief commercial officer. Gammack, a 25-year veteran of life sciences commercial operations, will leverage his...

Meet the Startup That's Giving Away Its CRISPR-Like Technology For Free

CRISPRis one of the most promising areas in biotech, but much of that potential has been locked behind expensive licensing schemes.

Inscripta Blogs

Inscripta Appoints Ron McGrath as Chief Financial Officer

Boulder, CO – April 30, 2019 – Inscripta, developer of the first scalable platform for benchtop Digital Genome Engineering, today announced the appointment of Ron McGrath as Chief Financial Officer. Mr. McGrath has held leadership and financial roles for more than 25 years in the biotechnology and i…

Inscripta Completes $20M Expansion of Series C Financing, Increasing Total Round to $105.5M

Continued support of existing investors will fund commercialization efforts, product launch later this year The post Inscripta Completes $20M Expansion of Series C Financing, Increasing Total Round to $105.5M appeared first on Inscripta.

In the First Year of Release, Inscripta’s MAD7 CRISPR Enzyme is Widely Adopted by the Gene-Editing Community

Existing investors contribute an additional $30 million to accelerate tools that will revolutionize genomic research The post In the First Year of Release, Inscripta’s MAD7 CRISPR Enzyme is Widely Adopted by the Gene-Editing Community appeared first on Inscripta.

Inscripta’s MAD7 Named a Top Innovation of 2018 by The Scientist

The award recognizes products that are set to revolutionize research and advance scientific knowledge. The post Inscripta’s MAD7 Named a Top Innovation of 2018 by The Scientist appeared first on Inscripta.

Inscripta Wins Rising Star Award from Colorado BioScience Association

Inscripta has been selected for the Colorado BioScience Association’s 2018 Rising Star Award The post Inscripta Wins Rising Star Award from Colorado BioScience Association appeared first on Inscripta.

Inscripta Announces Strategic Acquisition of Solana Biosciences

Boulder, Colo. – September 5, 2018 – Inscripta™, a leading gene-editing technology company, today announced the strategic acquisition of Solana Biosciences, a life sciences company founded by Illumina™ veterans. The post Inscripta Announces Strategic Acquisition of Solana Biosciences appeared first …
Show more

Inscripta Frequently Asked Questions

  • When was Inscripta founded?

    Inscripta was founded in 2015.

  • Who are Inscripta key executives?

    Inscripta's key executives are Kevin Ness, Ryan Gill and Don Masquelier.

  • How many employees does Inscripta have?

    Inscripta has 82 employees.

  • Who are Inscripta competitors?

    Competitors of Inscripta include Touchlight Genetics, Reneuron Group and Blueprint Genetics.

  • Where is Inscripta headquarters?

    Inscripta headquarters is located at 5500 Central Ave #220, Boulder.

  • Where are Inscripta offices?

    Inscripta has offices in Boulder and Pleasanton.

  • How many offices does Inscripta have?

    Inscripta has 2 offices.